Skip to main content

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

Active, not recruiting · Phase 3 · NCT05734105

Conditions: GIST

At a glance

Research payments reported, 2025
$6.2M
U.S. investigators named
20
Sites paid
25
Planned or actual enrollment
54

About the trial

Sponsor
Deciphera Pharmaceuticals, LLC
Tested
Ripretinib (drug), Sunitinib (drug)
Dates
Started 2023-12-13; completion 2028-12
Results posted
Not yet

This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon 9, 13, or 14 mutations. Upon disease progression as determined by an independent radiologic review, participants randomized to sunitinib will be given the option to either crossover to receive ripretinib 150 mg QD or discontinue sunitinib.

From ClinicalTrials.gov, last updated 2025-12-17. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Deciphera Pharmaceuticals Inc. reported $6.2M in research payments for this study in 2025 (341 payments).

Products named: Sutent, Qinlock

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Ut MD Anderson Cancer Center $1.3M
  • Ohsu Hospital and Clinics, OR $873,160
  • Cleveland Clinic, OH $791,171
  • The Feinstein Institutes for Medical Research $747,990
  • Moffitt Cancer Center $494,280
  • University of Virginia Medical Center, VA $293,212
  • Dana-Farbermass General Brigham Cancer Center Inc $291,300
  • University of Pittsburgh Cancer Institute Cancer Services $146,788
  • University of Washington Medical Ctr, WA $116,714
  • The Ohio State University $110,617
  • Mayo Clinic $108,606
  • Regents of the University of Minnesota $98,204
  • Yale University $93,750
  • Boston Medical Center, MA $88,903
  • University of Miami $80,131
  • Board of Regents of the University of Oklahoma Health Sciences Center $77,456
  • Mayo Clinic Jacksonville $77,200
  • The Johns Hopkins University $73,950
  • The Regents of the University of California San Diego Campus $73,950
  • Memorial Sloan Kettering Cancer Center $73,950
  • The Feinstein Institute for Medical Research $58,126
  • The Regents of the University of California $57,247
  • Johns Hopkins University $28,555
  • Memorial Sloankettering Cancer Center $27,948
  • Dana-Farber Mass General Brigham Cancer Care Inc $22,568

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.